• We initiate coverage with a fair value of SEK 12.19 per share
The prospects for gene therapies have raised the hopes and expectations of
patients, healthcare professionals and investors in the life sciences
industry. The first therapies have been approved, and more are on the way.
Gene therapies are expected to take off in the 2020s as global pharmaceutical
companies compete to position themselves in a field with great medical and
commercial potential. Swedish gene therapy specialist CombiGene focuses on
discovering promising projects, developing them into the clinical phase and
out-licensing them after achieving preclinical proof of concept.
Västra Hamnen initiates research coverage of CombiGene with a fair value of
SEK 12.19 per share.
Aktuellt
SENASTE
